Cempra to Present at Three Upcoming Investor Conferences

CHAPEL HILL, N.C., Sept. 01, 2016 (GLOBE NEWSWIRE) — Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced it will be participating in three upcoming investor conferences.

  • Baird Global Healthcare Conference – 2016, The New York Palace Hotel, New York, September 8, 2016 at 3:10 p.m. EDT.
  • Morgan Stanley Global Healthcare Conference, the Grand Hyatt Hotel, New York, September 12, 2016 at 1:05 p.m. EDT.
  • Ladenburg Thalmann 2016 Healthcare Conference, Sofitel Hotel, New York, September 27, 2016 at 12:00 p.m. EDT

A live audio webcast and archive of the presentations will be available on the company website at http://investor.cempra.com/events.cfm. Listeners are encouraged to visit the site prior to the scheduled presentation to register, download and install any necessary audio software.

About Cempra, Inc.

Cempra, Inc. is a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases. Cempra’s two lead product candidates are currently in advanced clinical development. Solithromycin has been successfully evaluated in two Phase 3 clinical trials for community acquired bacterial pneumonia (CABP) and applications for approval for both intravenous and oral capsule formulations have been accepted for review by the FDA and the EMA. Solithromycin is licensed to strategic commercial partner Toyama Chemical Co., Ltd., a subsidiary of FUJIFILM Holdings Corporation, for certain exclusive rights in Japan. Solithromycin is also in a Phase 3 clinical trial for uncomplicated urogenital urethritis caused by Neisseria gonorrhoeae or chlamydia. Cempra is contracted with BARDA for the development of solithromycin for pediatric use. Three formulations, intravenous, oral capsules and a suspension formulation are in a Phase 1b trial in children from birth to 17 years of age. Fusidic acid is Cempra’s second product candidate, which is being developed for acute bacterial skin and skin structure Infections (ABSSSI) and is also in an exploratory study for chronic oral treatment of refractory infections in bones and joints. Both products seek to address the need for new treatments targeting drug-resistant bacterial infections in the hospital and in the community. Cempra has also synthesized novel macrolides for non-antibiotic uses such as the treatment of chronic inflammatory diseases, endocrine diseases and gastric motility disorders. Cempra was founded in 2006 and is headquartered in Chapel Hill, N.C. For additional information about Cempra please visit www.cempra.com.

CONTACT: Company Contact:
John Bluth
Cempra, Inc.
+1 984 209 4534

Investor Contact:
Robert Uhl
Westwicke Partners, LLC
+1 858 356 5932

Media Contact:
Melyssa Weible
Elixir Health PR
+1 201 723 5805